Pulse Explorar nav.journalClub Debates Tendencias Investigadores Revistas

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

June 4, 2023Open Access

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

IMIngo K. MellinghoffMemorial Sloan Kettering Cancer Center

Martin J. van den BentNorthwestern University DBDeborah T. BlumenthalTel Aviv University

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

In patients with grade 2 IDH-mutant glioma, vorasidenib significantly improved progression-free survival and delayed the time to the next intervention. (Funded by Servier; INDIGO ClinicalTrials.gov number, NCT04164901.).

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma | Synapse

Cite This Study

Mellinghoff et al. (Sun,) studied this question.

synapsesocial.com/papers/69d81bdcb5518339b2ae2e5f https://doi.org/https://doi.org/10.1056/nejmoa2304194

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Ivosidenib in Isocitrate Dehydrogenase 1<i>–</i>Mutated Advanced Glioma2020 · 312 citations
2Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study2002 · 637 citations
3Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions2022 · 243 citations
4Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors2022 · 91 citations
5Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study2020 · 236 citations